LONDON, July 8 — Against the backdrop of a global struggle to catch cancer early, researchers at Queen Mary University of London have delivered what they describe as the largest study of its kind into a simple brush biopsy for oral cancer. The test, known as the qMIDSV3 oral brush biopsy assay, was evaluated by a cross-university team led by Queen Mary. The findings, published in the journal *Biomarker Research*, are based on an analysis of 1,090 brush biopsy samples drawn from 545 patients.
This scale, the researchers said, gives the study unusual weight in a field where early detection remains a stubborn challenge. Oral squamous cell carcinoma is the main form of oral cancer.
The qMIDSV3 assay works by collecting cells from the surface of the mouth — a non-invasive procedure that stands in sharp contrast to the tissue biopsy that has long been the standard for diagnosis. What is at stake here is the question of triage. Clinicians have wrestled with how to manage patients who present with potentially malignant oral disorders — lesions that might, or might not, become cancer.
The standard response has often been an invasive tissue biopsy. The Queen Mary-led study suggests a different path.
The researchers said the brush biopsy assay could spare more than 90% of low-risk patients from undergoing unnecessary invasive biopsies.
A test that addresses both diagnosis and triage
The study’s authors framed their work as addressing two linked challenges in oral cancer care: diagnosis and triage. The qMIDSV3 assay is designed to detect the presence of oral squamous cell carcinoma from cells brushed gently from the mouth’s lining. But it also stratifies risk, allowing clinicians to separate the low-risk majority from those who need urgent, deeper investigation.
The 1,090 samples analysed in the study represent a substantial evidence base. The sheer size of the cohort lends weight to the claim that the test can reliably identify which patients can safely avoid a tissue biopsy.
European context and the burden of oral cancer
The Queen Mary team’s work fits into a broader push toward minimally invasive diagnostics. The researchers acknowledged that the assay is not a replacement for tissue biopsy in high-risk cases. Rather, it is a triage tool — a way to decide who needs the more invasive procedure and who can be safely monitored.
The publication in *Biomarker Research* marks a milestone, but the path from research to routine clinical use is never straightforward. The qMIDSV3 assay will need to be validated in broader, more diverse populations, and its cost-effectiveness will need to be demonstrated.
For now, the Queen Mary-led team has provided a substantial piece of evidence. The study’s size — 1,090 samples from 545 patients — gives it statistical weight that smaller studies have lacked. The researchers have shown that a brush biopsy can, in the right context, identify the low-risk majority and spare them unnecessary surgery.
The wider picture is one of incremental progress. Oral cancer remains a disease where late diagnosis is common, and where the treatment can be disfiguring.
Any tool that moves the point of diagnosis earlier, and makes the diagnostic pathway less burdensome, is a step forward. The Queen Mary study suggests that the qMIDSV3 assay may be such a tool. Consult your doctor for medical advice.
